Transmission of malignancy with solid organ transplants.

Donor-derived malignancy is found in about 0.02-0.2% of allograft recipients. With an increasing number of older donors, this problem will gain more relevance in the future. We wish to review the current literature on tumor transmission with solid organ transplants and focus on the consequences of an extension of the donor pool, such as by the use of donors with a history of cancer. Finally, suggestions are made for screening regimens for living as well as cadaveric donors to minimize the risk of inadvertent tumor transmission.